Search results
Results From The WOW.Com Content Network
Patients with acute eosinophilic leukemia have a propensity for developing bronchospasm as well as symptoms of the acute coronary syndrome and/or heart failure due to eosinophilic myocarditis and eosinophil-based endomyocardial fibrosis. [1] [2] Hepatomegaly and splenomegaly are more common than in other variants of AML.
The overly stimulated CFU-Eos cells mature to apparently normal appearing but possibly overactive eosinophils which enter the circulation and may accumulate in and damage various tissues. The disorder is usually indolent or slowly progressive but may proceed to a leukemic phase sometimes classified as acute eosinophilic leukemia.
Acute eosinophilic leukemia, chronic myeloid leukemia, chronic myelomonocytic leukemia, and systemic mastocytosis with eosinophilia. [3] Treatment: Corticosteroids, Imatinib, medications to control eosinophil counts, and supportive care. [4] Frequency: 0.36 to 6.3 per 100,000. [3]
Conventionally, a leukocytosis exceeding 50,000 WBC/mm 3 with a significant increase in early neutrophil precursors is referred to as a leukemoid reaction. [2] The peripheral blood smear may show myelocytes, metamyelocytes, promyelocytes, and rarely myeloblasts; however, there is a mixture of early mature neutrophil precursors, in contrast to the immature forms typically seen in acute leukemia.
Eosinophilia is a condition in which the eosinophil count in the peripheral blood exceeds 5 × 10 8 /L (500/μL). [1] Hypereosinophilia is an elevation in an individual's circulating blood eosinophil count above 1.5 × 10 9 /L (i.e. 1,500/μL).
At least one case of FIP1L1-PDGFRA fusion gene-induced eosinophilic leukemia presenting with myeloid sarcoma and eosinophilia has been reported. This form of myeloid sarcoma is distinguished by its highly successful treatment with imatinib (the recommended treatment for FIP1L1-PDGRGA fusion gene-induced eosinophilic leukemia) rather than more aggressive and toxic therapy.
Biphenotypic acute leukaemia (BAL) is an uncommon type of leukemia which arises in multipotent progenitor cells which have the ability to differentiate into both myeloid and lymphoid lineages. [1] [2] [3] It is a subtype of "leukemia of ambiguous lineage". [4] The direct reasons leading to BAL are still not clear.
Current cure rates using stem cell therapy in dogs approximates that achieved in humans, 40-50%. When cost is a factor, prednisone used alone can improve the symptoms dramatically, but it does not significantly affect the survival rate. The average survival times of dogs treated with prednisone and untreated dogs are both one to two months. [1]